- Home
- CRT vs ALGS Comparison
CRT vs ALGS Comparison
Compare CRT & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRT | ALGS |
|---|---|---|
| Founded | 1991 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.5M | 49.7M |
| IPO Year | 1992 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CRT | ALGS |
|---|---|---|
| Price | $8.45 | $7.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $46.67 |
| AVG Volume (30 Days) | 26.2K | ★ 80.9K |
| Earning Date | 03-12-2026 | 03-09-2026 |
| Dividend Yield | ★ 8.11% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $5,621,913.00 | $2,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.41 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.07 | $3.76 |
| 52 Week High | $13.31 | $29.54 |
Technical Indicators
Market Signals| Indicator | CRT | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 53.14 | 33.96 |
| Support Level | $8.29 | $7.92 |
| Resistance Level | $8.85 | $8.39 |
| Average True Range (ATR) | 0.29 | 0.82 |
| MACD | -0.02 | -0.13 |
| Stochastic Oscillator | 51.43 | 4.99 |
Price Performance
Historical ComparisonAbout CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.